

## Disclosures

### Personal Commercial (23)

| Company Name                     | Relationship Category                                                            | Compensation Level       | Topic Area(s)                       |
|----------------------------------|----------------------------------------------------------------------------------|--------------------------|-------------------------------------|
| <i>Self</i>                      |                                                                                  |                          |                                     |
| Abbott                           | Research/Research Grants                                                         | Significant (>= \$5,000) | Acute Coronary Syndromes            |
| Abbott Laboratories              | Research/Research Grants                                                         | Significant (>= \$5,000) | Arrhythmias and Clinical EP         |
| Ablative Solutions, Inc          | Research/Research Grants                                                         | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| AHA                              | Research/Research Grants                                                         | Significant (>= \$5,000) | Acute Coronary Syndromes            |
| Biocardia                        | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |
| BIOTRONIK, INC.                  | Research/Research Grants                                                         | Significant (>= \$5,000) | Arrhythmias and Clinical EP         |
| CSL Behring LLC (CSLB)           | Research/Research Grants                                                         | Significant (>= \$5,000) | Acute Coronary Syndromes            |
| DCRI                             | Other - Multidisciplinary committee providing input to PCORI funded HERO studies | Modest (< \$5,000)       | Prevention                          |
| DOD                              | Research/Research Grants<br>‡ WARRIOR                                            | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| Evaheart, Inc                    | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |
| LivaNova USA, Inc.               | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |
| Medtronic, Inc                   | Research/Research Grants                                                         | Significant (>= \$5,000) | Arrhythmias and Clinical EP         |
| Medtronic, Inc.                  | Research/Research Grants                                                         | Modest (< \$5,000)       | Arrhythmias and Clinical EP         |
| Milestone pharmaceuticals        | Consultant Fees/Honoraria                                                        | Modest (< \$5,000)       | Arrhythmias and Clinical EP         |
| NIH                              | Research/Research Grants                                                         | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| NIH                              | Research/Research Grants                                                         | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| nih                              | Research/Research Grants                                                         | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| NIH                              | Research/Research Grants                                                         | Significant (>= \$5,000) | General Cardiology                  |
| Novartis                         | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |
| Novo Nordisk Inc.                | Consultant Fees/Honoraria                                                        | Modest (< \$5,000)       | Other                               |
| PCORI                            | Research/Research Grants                                                         | Significant (>= \$5,000) | Other                               |
| TIMI Study Group and AstraZeneca | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |
| XyloCor Therapeutics, Inc.       | Research/Research Grants                                                         | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies  |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name                     | Relationship Category                               | Compensation Level | Topic Area(s) |
|------------------------------------------------|-----------------------------------------------------|--------------------|---------------|
| <i>Self</i>                                    |                                                     |                    |               |
| Preventative Cardiovascular Nurses Association | Officer, Director, Trustee, or other Fiduciary Role | None (\$0)         | Prevention    |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

Agreement

---

**Certified Education Attestation** | Signed on 4/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 4/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 4/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 4/15/2024

---

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.